Navigation Links
Blood test serves as 'crystal ball' for heart transplant patients, UCLA-led study finds
Date:2/18/2014

A new UCLA-led study shows that a blood test commonly used to determine whether heart transplant recipients are rejecting their new organ can also predict potential rejection-related problems in the future.

Reporting in the online edition of the peer-reviewed journal Transplantation, researchers demonstrate how the AlloMap test, which uses a blood sample to measure changes in the expression of roughly a dozen genes, can be used over a period of time to assess the risk of dysfunction or rejection of a transplanted heart months before such an event may occur.

"For the first time, we can use genomic testing over multiple patient visits to go beyond intuition to understand not just how patients are doing now but how they are likely to be a few months from now," said Dr. Mario Deng, medical director of UCLA's Integrated Advanced Heart FailureMechanical SupportHeart Transplant Program and the study's principal investigator. "It's another step toward personalized medicine."

The discovery that transplant recipients' white blood cells contain this prognostic information on rejection, independent of how their transplanted heart may be functioning currently, could potentially improve care and outcomes, the researchers said. The findings represent a significant step in the movement toward using genomic-based testing to predict future clinical events and bolster the importance of similar tests being developed for recipients of other organs.

In the U.S., approximately 2,000 patients receive lifesaving heart transplants each year, and monitoring their immune systems for signs of rejection is a critical part of follow-up care. Until recently, however, the only way to diagnose rejection was through a heart-muscle biopsy, a painful and potentially risky procedure in which a heart catheter is inserted through a vein in the neck.

That changed with the development of the AlloMap gene-expression profiling test, which received clearance from the Food and Drug Administration in 2008. The test is now routinely used by a majority of U.S. heart transplant centers to monitor low-risk patients during follow-up care, resulting in a substantial reduction in the number of biopsies.

AlloMap, which is based on research Deng led in conjunction with more than a dozen of the largest U.S. heart transplant centers and the Brisbane, Calif.based biotech company XDx, measures the expression levels of 11 genes from a patient's blood sample, each of which is known to be associated with rejection risk.

"The AlloMap was the first FDA-cleared test allowing transplant centers to rule out rejection at the time of the visit," Deng said. "But until now, it has never been used to predict future events."

The current study is based on data originally collected by leading transplant centers and published in the New England Journal of Medicine in 2010. For that study, 600 heart transplant recipients were randomly assigned to be monitored for potential episodes of rejection either through routine biopsy or through the AlloMap test. The study found that AlloMap was equally as effective as biopsy at detecting rejection or dysfunction, and it resulted in increased patient satisfaction because it was less invasive.

The new study demonstrates for the first time the ability of the AlloMap test, when used over time, to predict future events.

Deng and colleagues noted that using gene-expression profiling to predict the future likelihood of patients experiencing rejection-related problems with their transplanted heart could change the way such patients are treated.

For example, those deemed to be at low risk for adverse events could be given lower doses of immunosuppressive drugs, which could reduce the significant side effects. On the other hand, patients found to be at high risk could be evaluated at shorter time intervals to determine the causes of the test-result variability, specifically to rule out rejection.

As of now, there are no similar tests to monitor the potential for rejection in other types of transplanted organs, but Deng said that active collaborative and multidisciplinary research programs at UCLA and elsewhere are working to bring genomic testing to these fields.


'/>"/>

Contact: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-2270
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Finding the right way to address a patient’s condition before ... is now getting on board. , “You do the right thing, at the right time, ... goes down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even ...
(Date:5/3/2016)... ... May 03, 2016 , ... The new web-based solution ... physician practices, to better grasp and implement HIPAA’s privacy, security, and data breach ... a well-defined, expert-created path to compliance. HIPAA Institute has positioned itself to be ...
(Date:5/3/2016)... ... May 03, 2016 , ... The American Medical Informatics ... Office of the National Coordinator for Health IT (ONC) with qualified support for ... including suspending and terminating certifications issued to Complete EHRs and Health IT Modules. ...
(Date:5/2/2016)... ... May 02, 2016 , ... Those who ... center can find some useful information in a new video released by Serenity ... video, which can be viewed on the Serenity Recovery YouTube channel, examines various ...
(Date:5/2/2016)... ... May 02, 2016 , ... As directed by its board of ... issues its full support to allow certified nurse practitioners (CNP) to practice to the ... worked under such supervision for three years and 3,600 hours. , In addition, HAP ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)...  Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical ... needs of recovery for a variety of clinical conditions. Founded in 2013, Forté spent ... http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... bekannt, dass sie einen entscheidenden Meilenstein durch ... Ein Aufruf zum Handeln, um Patientenresultate  bei ... trägt zu Fortschritten im Verständnis der Hepatischen ... ein Bewusstsein für Hepatische Enzephalopathie in der ...
(Date:5/2/2016)... Economies with Fastest Real GDP Annual Percentage Change, 2015  Real ... , Source: IMF and TechSci Research   According ... , Russia , India , ... fastest GDP growth during the first decade of the 21 st century. ... Brazil and Russia , along with policy uncertainty ...
Breaking Medicine Technology: